Tag Archives: Tricuspid valve

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Sex-Related Differences in Clinical Outcomes after Transcatheter Tricuspid Valve Intervention

Sex-Related Differences in Clinical Outcomes after Transcatheter Tricuspid Valve Intervention

We are aware of sex related differences when it comes to comorbidities, physiopathology and disease evolution in patients with tricuspid regurgitation (TR).  TR is more prevalent among women, whereas among men, coronary artery disease is more prevalent, with worse left ventricular ejection fraction and 10-year survival rate. Transcatheter tricuspid valve intervention (TTVIs) has surged as

Válvula Tricúspide: nuevas opciones de tratamiento estructural percutáneo

Watch Again Tricuspid Valve: New Options for Structural Percutaneous Treatment

Enjoy once again a new SOLACI Sessions event: “Tricuspid Valve: New Options for Structural Percutaneous Treatment” on our YouTube channel. The event, sponsored by P&F, was attended by renowned opinion leaders in the region and featured important dissertations and case study discussions. Watch it here below! Tricuspid Valve: New Options for Structural Percutaneous Treatment

La insuficiencia renal post tratamiento borde a borde tricuspídeo impacta en el pronóstico

Prognostic Impact of Acute Kidney Injury Following Tricuspid Transcatheter Edge-to-Edge Repair

Tricuspid failure (TF) mostly affects the elderly and, because of this, is associated with comorbidities that increase surgical risk.  Tricuspid edge to edge repair (TEER) has surged as a valid alternative for the mitral valve in high-risk patients and, at present, is increasingly being used for tricuspids.  One of the complications following TEER is acute

ATC sobre arterias nativas o puentes venosos, ¿cuál tiene mejor pronóstico?

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart failure (HF)—often requiring hospitalization—and with mortality. Surgery in this valve is not simple and has high morbidity and mortality rates due to its comorbidities. Currently, a percutaneous strategy for its resolution is under development, but we still do

TRICVALVE en pacientes con Insuficiencia tricuspídea severa: resultados alentadores a 6 meses

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk that cannot get surgery, the endovascular option has become an attractive solution this past decade.  Transcatheter intervention has focused on edge-to-edge repair and valve replacement. However, their success depends on anatomical characteristics and imaging guidance effectiveness.  The bicaval

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Jenavalve Trilogy System: Valve for Severe Aortic Regurgitation

Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis.  This study included 45 patients with severe AR. Primary end

ACC 2022

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device. Forty-six completed the 12-month follow-up. At 1-year follow-up, the major events endpoint was 16.9%; the most frequent event was bleeding (9.2%). In addition, there were three cases of stroke, one reintervention, two vascular access complications, and five cardiovascular-related

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Are Self-Expandable Valves a Valid Option in Bicuspids?

Bicuspid Aortic Valves (VAV) are challenging for TAVR given its anatomical characteristics and the important presence of calcification. However, current data are promising.  Even though traditionally excluded from the larger randomized studies, self-expandable valves appear to have similar evolution to tricuspid aortic valves (TAV) with severe stenosis.  Researchers looked at the Low-Risk Bicuspid Study and

Válvula Bicúspide

Good Evolution of Bicuspid Valves with EVOLUTE or EVOLUTE PRO

Courtesy of Dr. Carlos Fava. TAVR has matured over time and has advanced onto low risk patients, but one of its greatest challenges continues to be bicuspid valve patients. These represent between 1% and 2% of the population and over 20% of young adults requiring surgical valve replacement (SAVR).  The study looked at 27,086 patients

El estudio SOURCE 3 confirma los buenos resultados de la válvula SAPIEN 3 a un año de seguimiento

SAPIEN 3: Good Outcomes in Bicuspids

Courtesy of Dr. Carlos Fava. Bicuspid aortic valves are found in approximately 2% of patients and represent the most frequent cause of aortic stenosis in young adults requiring valve replacement. Though TAVR has advanced significantly, this entity has not yet been included in the different randomized studies. At present, we have data from different reports,

Top